<?xml version="1.0" encoding="utf-8"?><feed xmlns="http://www.w3.org/2005/Atom" ><generator uri="https://jekyllrb.com/" version="4.4.1">Jekyll</generator><link href="/feed.xml" rel="self" type="application/atom+xml" /><link href="/" rel="alternate" type="text/html" /><updated>2026-02-25T12:34:18+00:00</updated><id>/feed.xml</id><title type="html">Synaptic Transmissions</title><subtitle>Central Latency Reduction</subtitle><author><name>Habakuk Hain</name></author><entry><title type="html">General anesthesia versus conscious sedation for thrombectomy.</title><link href="/posts/dienstag-1/" rel="alternate" type="text/html" title="General anesthesia versus conscious sedation for thrombectomy." /><published>2026-02-24T00:00:00+00:00</published><updated>2026-02-24T00:00:00+00:00</updated><id>/posts/1</id><content type="html" xml:base="/posts/dienstag-1/"><![CDATA[<p><strong>Problem</strong>: Anesthesiology definitely needs to be involved early in stroke codes where thrombectomy is an option, but whether general anesthesia versus conscious sedation provides superior outcomes during endovascular thrombectomy for large vessel occlusion stroke has been an open question.</p>

<p><strong>Result</strong>: General anesthesia significantly improved both revascularization success (OR 1.79) and functional independence in appropriately selected patients (OR 1.58) without safety concerns.</p>

<p><strong>Open Questions</strong>: The optimal anesthetic protocol and which specific patient subgroups benefit most from general anesthesia during thrombectomy remain to be defined.</p>]]></content><author><name>Habakuk Hain</name></author><category term="dienstag" /><category term="thrombectomy" /><category term="general anesthesia" /><category term="functional outcomes" /><summary type="html"><![CDATA[Problem: Anesthesiology definitely needs to be involved early in stroke codes where thrombectomy is an option, but whether general anesthesia versus conscious sedation provides superior outcomes during endovascular thrombectomy for large vessel occlusion stroke has been an open question.]]></summary></entry><entry><title type="html">Deep brain stimulation for epilepsy.</title><link href="/posts/transmission-5/" rel="alternate" type="text/html" title="Deep brain stimulation for epilepsy." /><published>2026-02-23T00:00:00+00:00</published><updated>2026-02-23T00:00:00+00:00</updated><id>/posts/5</id><content type="html" xml:base="/posts/transmission-5/"><![CDATA[<p><strong>Problem</strong>: Despite multiple DBS targets being used for drug-resistant epilepsy, there was no comprehensive analysis of how precise electrode placement within targets affects clinical outcomes.</p>

<p><strong>Result</strong>: Electrode placement accuracy significantly correlates with seizure reduction, particularly for ANT-DBS where closer proximity to mammillothalamic tract junction predicts better outcomes (r=-0.55, p&lt;0.001).</p>

<p><strong>Open Questions</strong>: Prospective validation of these targeting relationships and standardization of electrode placement techniques across centers remain to be established.</p>]]></content><author><name>Habakuk Hain</name></author><category term="transmission" /><category term="deep brain stimulation" /><category term="drug-resistant epilepsy" /><category term="thalamic targeting" /><summary type="html"><![CDATA[Problem: Despite multiple DBS targets being used for drug-resistant epilepsy, there was no comprehensive analysis of how precise electrode placement within targets affects clinical outcomes.]]></summary></entry><entry><title type="html">Comparing effectiveness of newer antiseizure medications.</title><link href="/posts/transmission-4/" rel="alternate" type="text/html" title="Comparing effectiveness of newer antiseizure medications." /><published>2026-02-22T05:00:00+00:00</published><updated>2026-02-22T05:00:00+00:00</updated><id>/posts/4</id><content type="html" xml:base="/posts/transmission-4/"><![CDATA[<p><strong>Problem</strong>: Direct comparative effectiveness data among newer antiseizure medications in drug-resistant focal epilepsy has been limited. This is largely because prospective studies are hard to design and to conduct ethically. Withholding treatment in placebo-controlled trials can often times not be done ethically and for most patients eligible to enrol in such studies, seizures are relatively rare events, leading to a large sample sizes for sufficient statistical power.</p>

<p><strong>Result</strong>: Cenobamate demonstrated superior efficacy across all measures (50% response rate, seizure freedom, notably also retention) compared to three other newer ASMs, despite causing more adverse effects.</p>

<p><strong>Open Questions</strong>: Prospective head-to-head trials and longer-term safety data are still somewhat necessary to confirm these real-world effectiveness findings and better characterize cenobamateâ€™s risk-benefit profile. For now, all we have to counsel patients is that there are some hints that cenobamate could be more effective in stopping seizures than other modern drugs, and the associated risks may be worth it.</p>]]></content><author><name>Habakuk Hain</name></author><category term="transmission" /><category term="cenobamate" /><category term="drug-resistant epilepsy" /><category term="comparative effectiveness" /><summary type="html"><![CDATA[Problem: Direct comparative effectiveness data among newer antiseizure medications in drug-resistant focal epilepsy has been limited. This is largely because prospective studies are hard to design and to conduct ethically. Withholding treatment in placebo-controlled trials can often times not be done ethically and for most patients eligible to enrol in such studies, seizures are relatively rare events, leading to a large sample sizes for sufficient statistical power.]]></summary></entry><entry><title type="html">MS progression despite high-efficacy therapy.</title><link href="/posts/transmission-3/" rel="alternate" type="text/html" title="MS progression despite high-efficacy therapy." /><published>2026-02-21T15:04:48+00:00</published><updated>2026-02-21T15:04:48+00:00</updated><id>/posts/3</id><content type="html" xml:base="/posts/transmission-3/"><![CDATA[<p><strong>Problem</strong>: There is a paradigmatic shift in MS care on its way as evidence is accumulating that using high-efficacy therapies (HET) in early stages of the disease prevents relapses and decreases evidence of disease activity on sequential MRI scans. Whether high-efficacy MS therapies can prevent progression independent of relapse and MRI activity (PIRMA) is an open questions.</p>

<p><strong>Result</strong>: HET showed no meaningful advantage over moderate-efficacy therapies in preventing PIRMA, despite superior control of relapse-associated and MRI-associated worsening.</p>

<p><strong>Open Questions</strong>: The underlying mechanisms driving PIRMA remain unclear, and whether alternative therapeutic strategies beyond current anti-inflammatory approaches might be needed to address this form of progression.</p>]]></content><author><name>Habakuk Hain</name></author><category term="transmission" /><category term="PIRMA" /><category term="high-efficacy therapies" /><category term="multiple sclerosis" /><summary type="html"><![CDATA[Problem: There is a paradigmatic shift in MS care on its way as evidence is accumulating that using high-efficacy therapies (HET) in early stages of the disease prevents relapses and decreases evidence of disease activity on sequential MRI scans. Whether high-efficacy MS therapies can prevent progression independent of relapse and MRI activity (PIRMA) is an open questions.]]></summary></entry><entry><title type="html">ALS Roundup</title><link href="/posts/convergence-1/" rel="alternate" type="text/html" title="ALS Roundup" /><published>2026-02-21T00:00:00+00:00</published><updated>2026-02-21T00:00:00+00:00</updated><id>/posts/1</id><content type="html" xml:base="/posts/convergence-1/"><![CDATA[<p>There is a lot of movement in the ALS space. Some recent advances include insight into the pathomechanism of one genetic variant and reports of the first successful treatment with no evidence of disease progression of another genetic variant.</p>]]></content><author><name>Habakuk Hain</name></author><category term="convergence" /><summary type="html"><![CDATA[There is a lot of movement in the ALS space. Some recent advances include insight into the pathomechanism of one genetic variant and reports of the first successful treatment with no evidence of disease progression of another genetic variant.]]></summary></entry><entry><title type="html">Recombinant zoster vaccine and dementia risk.</title><link href="/posts/transmission-2/" rel="alternate" type="text/html" title="Recombinant zoster vaccine and dementia risk." /><published>2026-02-21T00:00:00+00:00</published><updated>2026-02-21T00:00:00+00:00</updated><id>/posts/2</id><content type="html" xml:base="/posts/transmission-2/"><![CDATA[<p><strong>Problem</strong>: There is converging evidence that live zoster vaccines reduce dementia risk, but comparable evidence is lacking for the recombinant zoster vaccine (RZV).</p>

<p><strong>Result</strong>: RZV vaccination showed a statistically significant 51% reduction in dementia risk (aHR 0.49), with 27% reduction persisting after controlling for healthy vaccinee bias.</p>

<p><strong>Open Questions</strong>: The mechanistic basis for this protective effect remains unclear, whether through direct neuroprotection, reduced neuroinflammation, or prevention of subclinical reactivations.</p>]]></content><author><name>Habakuk Hain</name></author><category term="transmission" /><category term="recombinant zoster vaccine" /><category term="dementia prevention" /><category term="neuroinflammation" /><summary type="html"><![CDATA[Problem: There is converging evidence that live zoster vaccines reduce dementia risk, but comparable evidence is lacking for the recombinant zoster vaccine (RZV).]]></summary></entry><entry><title type="html">Complement deposition in NMOSD, MOGAD, and MS.</title><link href="/posts/transmission-1/" rel="alternate" type="text/html" title="Complement deposition in NMOSD, MOGAD, and MS." /><published>2026-02-17T00:00:00+00:00</published><updated>2026-02-17T00:00:00+00:00</updated><id>/posts/1</id><content type="html" xml:base="/posts/transmission-1/"><![CDATA[<p><strong>Problem</strong>: The role of complement in MOGAD and MS pathogenesis remains unclear despite established complement involvement in NMOSD. This is particularly interesting since we have effective complement inhibitors as a potential therapeutic option.</p>

<p><strong>Result</strong>: MOGAD exhibits two distinct pathological phenotypes based on complement C9neo deposition intensity, with the more destructive pattern of intense C9neo deposition (27% of cases) associated with oligodendrocyte loss and increased mortality.</p>

<p><strong>Open Questions</strong>: Whether MOGAD pathological subtypes correlate with specific clinical features, treatment responses, or can be predicted by biomarkers in living patients remains unknown.</p>]]></content><author><name>Habakuk Hain</name></author><category term="transmission" /><category term="complement deposition" /><category term="NMOSD pathology" /><category term="MOGAD subtypes" /><summary type="html"><![CDATA[Problem: The role of complement in MOGAD and MS pathogenesis remains unclear despite established complement involvement in NMOSD. This is particularly interesting since we have effective complement inhibitors as a potential therapeutic option.]]></summary></entry></feed>